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Merozoite surface protein 3 (MSP3) is a target of antibody-dependent cellular inhibition (ADCI), a protective
mechanism against Plasmodium falciparum malaria. From the C-terminal half of the molecule, 6 overlapping
peptides were chosen to characterize human immune responses. Each peptide defined at least 1 non–cross-
reactive B cell epitope. Distinct patterns of antibody responses, by level and IgG subclass distribution, were
observed in inhabitants of a malaria-endemic area. Antibodies affinity purified toward each peptide differed
in their functional capacity to mediate parasite killing in ADCI assays: 3 of 6 overlapping peptides had a major
inhibitory effect on parasite growth. This result was confirmed by the passive transfer of anti–MSP3 antibodies
in vivo in a P. falciparum mouse model. T helper cell epitopes were identified in each peptide. Antigenicity
and functional assays identified a 70–amino acid conserved domain of MSP3 as a target of biologically active
antibodies to be included in future vaccine constructs based on MSP3.
The asexual blood-stage multiplication of the malarial
parasite is responsible for the acute symptoms of malaria
in humans. Epidemiological observations have shown
that adults living in endemic areas, although they are
constantly reinfected and frequently carry parasites, con-
trol their levels of parasitemia and show substantial clin-
ical resistance, compared with children [1]. Repeated in-
fections and continued exposure to the parasite are
required to reach this level of immunity against disease
[2]. This state of naturally acquired immunity against
disease, a phenomenon that is called premunition [3],
is not a sterile immunity and is marked by chronic low-
grade parasitemia without clinical symptoms.
The passive transfer of serum IgG from clinically
immune individuals has been shown to be able to con-
trol disease and the level of parasitemia in nonprotect-
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ed individuals who are exposed to geographically di-
verse parasite strains [4–6]. We have earlier shown
that the protection afforded by IgG has no major direct
effect on parasite invasion and growth in red blood
cells (RBCs)—rather, it acts in association with blood
monocytes through an antibody-dependent cellular in-
hibition (ADCI) mechanism that inhibits parasite de-
velopment [7]. The cytophilic nature of protective IgG
has been established [8, 9], and the importance of these
antibodies in protection against malaria has also been
demonstrated in other independent studies [10, 11].
Our search for the targets of the protective antibod-
ies, using ADCI as a functional assay, led us to identify
merozoite surface protein 3 (MSP3) as one such target
[12]. MSP3 is associated with merozoite surface mol-
ecules, possibly through the coiled-coil structures that
have been predicted to be formed by the heptad repeats
and the C-terminal leucine zipper domain [13]. The
N-terminal part of the molecule consists of regions that
are polymorphic among different strains. In contrast,
the C-terminal part of the molecule is highly conserved
among the various isolates of the parasite [14, 15], and
it is this region that was earlier identified by screening
of a Plasmodium falciparum expression library by use
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of functional ADCI assays [12]. Previous studies of MSP3 have
focused only on a 27-aa region (aa 184–210, corresponding to
the 3D7 strain, MSP3b) of the C-terminal part, which was
earlier identified as a target of protective antibody response in
hyperimmune serum samples [12].
We decided to further characterize the antigenicity of other
regions in the C-terminal part of the molecule. Six overlapping
peptides were designed (MSP3a, MSP3b, MSP3c, MSP3d, MSP3e,
and MSP3f), each of which represented a different region of
the conserved C-terminal part of the molecule. They were used
to analyze the naturally occurring immune responses in indi-
viduals from the malaria-endemic village of Dielmo, Senegal,
and their potential relationship to protection from malaria dis-
ease. The functional role of human antibodies specific to each
region was assessed under in vitro conditions in the ADCI assay
and was further confirmed by passive transfer in vivo in an
immunodeficient mouse model grafted with P. falciparum–in-
fected human RBCs [16, 17].
This process led us to identify a 70-aa region of MSP3 as
the target for naturally occurring protective antibody responses.
This region thus defines the minimal domain essential for the
design of any vaccine construct based on MSP3.
MATERIALS AND METHODS
Antigens. MSP3 recombinant protein constructs and pep-
tides were designed on the basis of the P. falciparum 3D7 strain
sequence (NCBI protein_id, NP_700818.1). Two recombinant
hexahistidine-tagged proteins, MSP3-NTHis21–184 and MSP3-
CTHis191–354, were purified as described elsewhere [18]. The 6
peptides (MSP3a167–191, MSP3b184–210, MSP3c203–230, MSP3d211–252,
MSP3e275–307, and MSP3f302–354) correspond to the conserved re-
gion of MSP3 C-terminal region. A small region (aa 253–274;
72% glutamic acid) was excluded from this analysis because
glutamate-rich antigenic determinants exhibit cross-reactivity
among several different P. falciparum antigens [19]. The pep-
tides were synthesized according to standard peptide synthesis
procedures [20].
Human serum and lymphocyte samples. For the affinity
purification of antibodies specific to each MSP3 region, we used
serum samples from 30 hyperimmune individuals from Ivory
Coast that had been previously used for passive-transfer ex-
periments in Thai patients with malaria and were found to be
effective in controlling disease and parasitemia [6].
For immunoepidemiological studies, we used plasma sam-
ples from 48 permanent residents of the village of Dielmo,
Senegal, who had various degrees of exposure to malaria (age,
3.5–53.4 years; mean age, years; mean stay in the13.1 1.8
village, 707/730 days of follow-up). In this region, malaria
transmission is intense and perennial (∼200 infected mosquito
bites/person/year); over the course of 2-year period, the mean
number of malaria attacks was episodes/person. Nine-2.4 5.4
teen individuals had no malaria attack (mean age, 15.7 3.1
years), whereas 29 individuals had at least 1 malaria attack
(mean age, years) during the next 2 years. All in-11.4 2.2
habitants of Dielmo were actively monitored by medical doctors
on a daily basis for febrile episodes, and those due to malaria
were accurately diagnosed as described elsewhere [21]. This
allowed us to examine the pattern of the IgG isotype response
toward different regions of MSP3 in individuals who were
clearly distinguishable as “protected” (no malaria attack) or
“nonprotected” (1 malaria attack) during the 2-year follow-
up period of the study. This group was representative of the
whole village in terms of age distribution, with respect to oc-
currence or absence of malaria attack.
Mononuclear cells obtained from inhabitants of Dielmo were
transported within 4 h to laboratories in Dakar and used for
T cell proliferation and the determination of interferon (IFN)–
g against MSP3a, MSP3b, and MSP3c peptides, according to
methods described elsewhere [22, 23]. In brief, the proliferative
responses of the cells were assessed in quadruplicate in 96-well
round-bottomed plates (Nunclon; Nunc) by incubation for 6
days at 37C in 5% CO2 in the presence of each peptide used
at 10 mg/mL, followed by the addition of 1 mCi of [3H]thy-
midine overnight and counting of the incorporated radioac-
tivity in a liquid scintillation counter. Unstimulated cultures
served as negative controls, and purified protein derivative and
phytohemagglutinin were used as positive controls. The IFN-
g concentration in pooled supernatants from quadruplicate
wells was assessed by a capture ELISA performed in duplicate,
by use of the anti–human IFN-g monoclonal antibody (MAb)
350B10G6 and biotin-labeled MAb 67F12A8 (Biosource) for
coating and revealing, respectively, according to the manufac-
turer’s instructions. The reaction was revealed by use of strep-
tavidin–horseradish peroxidase and tetra-methyl benzidine
chromogen, and the optical density was measured at 450 nm.
For practical reasons, mainly the number of cells available per
donor, the other 3 peptides used for antibody assays could not
be included in T cell assays. Lymphoproliferation studies were
performed with samples from 61 inhabitants (29 female and
32 male; mean age, 27.31 years), and IFN-g secretion was stud-
ied in 31 inhabitants (19 female and 12 male; mean age, 33.94
years). The 3 peptides proved to induce no significant response
in peripheral blood mononuclear cells from 16 control, non–
malaria-exposed donors (data not shown), which indicated that
they had no mitogenic or superantigenic effect.
ELISA. The ELISA was performed for the detection of
total IgG and subclasses, as described elsewhere [8, 9]. Mono-
clonal mouse anti–human subclasses IgG1–IgG4 (clones NL16
[Boehringer], HP6002 [Sigma], Zg4 [Immunotech], and RJ4
[Immunotech]) were selected for their affinity and reactivity
for African allotypes and were used as secondary antibodies at
dilutions of 1:2000, 1:5000, 1:5000, and 1:1000, respectively.
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The specific reactivity of each serum sample was obtained
by subtracting the optical density value of a control protein
(0.25 mg of bovine serum albumin/well) from that of the test
antigens. For calculating the threshold of significance of anti-
body responses, a set of 8 randomly selected serum samples
from individuals never exposed to malaria was tested against
each antigen, as controls. Results were expressed as the ratio
of the mean optical density from test serum samples to the
mean optical density of control subset + 3 the SD of the
control serum samples. Serum samples were considered to be
positive for ratios 1.
Affinity purification of antibodies. Because the ADCI as-
say requires the cooperation of antibodies with the Fc-g RII
receptor [7], a group of 30 hyperimmune serum samples from
individuals from Ivory Coast were first screened for IgG sub-
class distribution against different MSP3 peptides and recom-
binants. Serum samples were selected for the affinity purifi-
cation of antibodies against any given MSP3 construct on the
basis of their high reactivity against that region, with minimal
reactivity toward the adjacent peptides and a high content of
cytophilic IgG antibodies (IgG1 and IgG3). Independent serum
pools (each of which was made up of 5–7 individual serum
samples) were used to affinity purify antibodies to different
regions of MSP3. The ratios of cytophilic to noncytophilic IgG
subclasses (IgG1 + IgG3:IgG2 + IgG4) of the serum pools used
were estimated to be 9.56 for MSP3NT, 4.25 for MSP3CT, 1.29
for MSP3a, 3.86 for MSP3b, 1.29 for MSP3c, 4.58 for MSP3d,
1.59 for MSP3e, and 3.68 for MSP3f. Previous studies have
shown that the profile of cytophilic antibodies observed in af-
finity-purified antibodies was similar to that of the serum sam-
ple pool used for affinity purification (S. Singh, S. Soe, and P.D.,
unpublished data).
Affinity purification was done as described elsewhere [24],
by use of a 2.5% aqueous suspension of polystyrene beads
(mean diameter, 10 mm; Polysciences) to coat the peptides or
recombinant proteins. Specific antibodies were eluted by use
of 0.2 mol glycine/L (pH 2.5) and were immediately neutralized
to pH 7.0 by use of a 2 mol/L aqueous Tris solution. Affinity-
purified antibodies were dialyzed extensively against PBS fol-
lowed by RPMI and were concentrated by use of Centricon
concentrators (Millipore), filter sterilized, and, after the ad-
dition of 1% albumax (Gibco BRL), stored at 4C. Affinity-
purified antibodies were used at a concentration of 10 mg/mL
in ELISA to ascertain their specificity.
Immunofluorescence assay (IFA). Because the ability of
the antibodies to recognize the native parasite protein is the
critical factor in biological assays, IFA was used to adjust the
concentration of affinity-purified antibodies. IFA was per-
formed on air-dried, acetone-fixed, thin smears of P. falciparum
mature schizonts, as described elsewhere [25], to assess the
binding activity of affinity-purified antibodies to the parasite
protein. The effective concentration of each antibody was ad-
justed to a 1:200 IFA end-point titer for use in functional assays.
Functional in vitro antibody assays. The antibody-
dependent, monocyte-mediated ADCI assays were performed
in duplicate by use of laboratory-maintained strains 3D7 and
Uganda Palo-Alto, as described elsewhere [7]. Monocytes from
healthy, non–malaria-exposed donors were prepared as de-
scribed elsewhere [7]. The affinity-purified antibodies, adjusted
to a concentration yielding a 1/200 IFA end-point titer, were
added at a rate of 10 mL in 90 mL of complete culture medium,
which yielded a final titer of 1/20 in the ADCI assay. After
cultivation for 96 h, the level of parasitemia was determined
on Giemsa-stained thin smears from each well by the micro-
scopic examination of 50,000 erythrocytes. Monocyte-de-
pendent parasite inhibition is expressed as the specific growth
inhibition index (SGI): of parasitemiaSGIp 1 ([percentage
with monocytes and test IgG/percentage of parasitemia with
test IgG)/(percentage of parasitemia with monocytes and nor-
mal IgG/percentage of parasitemia with normal .IgG]) 100
Although the SGI calculation takes into account a possible
direct antiparasite effect of monocytes, because this is observed
with 10%–15% of monocyte preparations, we excluded them
as an additional precaution.
Passive immunization of P. falciparum–infected immuno-
compromised mice. The use of the P. falciparum–human RBC
(HuRBC)–Beige-Xid-Nude (BXN) mouse model for assessing
the effect of antibodies on different blood-stage antigens of P.
falciparum has been detailed elsewhere [16]. In brief, 6–8-week-
old male BXN mice (Charles River Laboratories), manipulat-
ed under pathogen-free conditions, were treated with liposomes
that contained dichloromethylenediphosphonate (Roche Diag-
nostics) and antipolymorphonuclear neutrophil MAb NIMP-R14
(NIMR), to reduce their innate immune response. P. falciparum–
infected human RBCs were injected intraperitoneally (ip) on day
0, and uninfected RBCs were injected at 4-day intervals. The level
of blood parasitemia was examined microscopically. Mice with
stable parasitemia (0.1%–1%) were injected ip with hu-63 10
man peripheral blood monocytes positively selected by CD14+
magnetic beads (MACS; Miltenyi Biotech), followed 24 h later
by the injection of monocytes together with 200 mL of63 10
affinity-purified antibodies to MSP3 at a 1:200 IFA end-point
titer, as described above. Nonspecific esterase staining [7] showed
that 198% of CD14+ cells were monocytes.
Statistical analysis. Univariate analysis was performed by
use of the Mann-Whitney U test. Fisher’s exact test was used
for the contingency analysis. The association between the risk
of malaria attack and the level of antibodies was tested with
JMP software (SAS Institute), by use of a stepwise regression
model in which we controlled for the confounding effect of
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Figure 1. Schematic presentation of Plasmodium falciparum merozoite surface protein 3 (MSP3) and the design of MSP3 recombinant proteins
(MSP3-NTHis and MSP3-CTHis) and peptides (MSP3a, MSP3b, MSP3c, MSP3d, MSP3e, and MSP3f). The representation of the N-terminal part of
MSP3 is compressed here (dotted line). DG210 represents the lgt11 expression clone originally identified as the target of protective antibodies [8].
The nos. show amino-acid positions for each region on the basis of the sequence derived from 3D7 strain.
Figure 2. Total IgG response against different regions of merozoite surface protein 3 (MSP3) in hyperimmune serum samples ( ) fromnp 30
individuals from Ivory Coast, used to prepare protective IgG for passive-transfer experiments in humans [6]. Antibody reactivity was considered to be
positive if the ratio of the mean optical density of the test serum samples to the mean optical density of control serum samples + 3  the SD of
the control serum sample was 1. The figure represents the mean antibody titer (expressed as ratio) of positive serum samples against each region.
The table shows the percentage prevalence of positive serum samples reactive to different regions of MSP3, in terms of total IgG.
age. The analysis of variance was applied to the regression mod-
el. The test of the null hypothesis was based on the variance
ratio denoted by F, and departures from the null hypothesis
tended to give values of F that were greater than unity.
RESULTS
Non–cross-reactive B cell epitopes defined by each of the 6 MSP3
C-terminal peptides. IgG responses were measured against
different regions of the MSP3 C terminal (figure 1) in a group
of 30 hyperimmune serum samples from individuals from Ivory
Coast. As shown in figure 2, there were differences in the levels
and prevalence of IgG toward each region, but antibody responses
were detected against each of the C-terminal peptides.
Antibodies were then affinity purified from selected hyper-
immune serum samples specific to each peptide and examined
for their reactivity against the other peptides. In this way, it
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Table 1. Specificity of affinity-purified human anti–merozoite
surface protein 3 (MSP3) antibodies, as determined by ELISA.
Antibody MSP3a MSP3b MSP3c MSP3d MSP3e MSP3f
Anti-MSP3a 0.78 0.09 0.08 0.08 0.09 0.08
Anti-MSP3b 0.05 1.11 0.09 0.08 0.09 0.07
Anti-MSP3c 0.07 0.10 1.04 0.09 0.09 0.08
Anti-MSP3d 0.10 0.08 0.16 1.01 0.09 0.09
Anti-MSP3e 0.08 0.08 0.08 0.08 0.95 0.10
Anti-MSP3f 0.07 0.07 0.08 0.08 0.10 0.92
NOTE. Mean optical density values at 450 nm from duplicate wells are
shown. All the peptides were used under identical coating conditions. Bold
type represents positive reactivity.
Figure 3. Prevalence and mean titer of antibodies against different regions of merozoite surface protein 3 (MSP3) in serum samples ( ) fromnp 48
Dielmo, Senegal. Antibody reactivity was considered to be positive if the ratio of the mean optical density of test serum samples to the mean optical
density of control serum samples + 3  the SD of the control serum samples was 1. The figure represents antibody titers (expressed as a ratio)
of the positive serum samples against each region. The table shows the percentage prevalence of positive serum samples reactive to different regions
of MSP3, in terms of IgG isotype.
was possible to affinity purify antibodies that were specific to
each peptide but did not show cross-reactivity with other
regions (table 1). These observations indicated that each of the
peptides covering the MSP3 C terminal defines at least 1 B cell
epitope that does not share antigenic determinants with other
regions. Each of the affinity-purified antibodies was also found
to be positive in IFAs of P. falciparum asexual blood stages,
which indicates that antipeptide antibodies were reactive with
the native parasite protein (data not shown).
Distinct isotype patterns of the IgG response toward dif-
ferent MSP3 peptides. We analyzed plasma from 48 indi-
viduals, 3–53 years old, from the endemic village of Dielmo,
Senegal, to study the distribution and pattern of IgG isotype
response against the different regions of the C-terminal part of
MSP3 defined by the peptides. As shown in figure 3, both the
level of antibody response and the pattern of IgG isotype were
distinct against each region. The prevalence of responders var-
ied for each region of MSP3 (6.25%–60.41% for IgG1, 4.16%–
47.91% for IgG3, 0%–10.41% for IgG2, and 0%–12.5% for
IgG4). We found that antibodies to MSP3a and MSP3e were
less prevalent, and, when they were present, they were detected
only at low levels. Antibodies to MSP3b, MSP3c, MSP3d, and
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MSP3f were the most prevalent and were predominantly of
cytophilic subclasses. Among the cytophilic isotypes, IgG3 reac-
tivity was found to be predominant against MSP3b, MSP3c,
and MSP3d. By contrast, IgG1 reactivity against MSP3f was
stronger and more prevalent than that against IgG3. This sug-
gests that the antibody response elicited to any region of MSP3
was not dependent on a response to other regions.
It had been observed earlier that the cytophilic IgG response
plays an important role in protection against malaria [8–11].
We further addressed the relationship between clinical protec-
tion that had been monitored on a daily basis and the pattern
of isotype responses observed against each peptide. In the pres-
ent study, protection was defined as the absence of any clinical
malaria attack during the 2 years after plasma samples were ob-
tained. Higher IgG3 titers against MSP3b, MSP3c, and MSP3d
were observed among protected, compared with nonprotect-
ed, subjects. An association between the levels of IgG3 anti-
bodies directed to MSP3b and MSP3d and protection from oc-
currence of malaria attack ( and .057, respectively) wasPp .037
observed. In the case of MSP3c, this association did not reach
statistical significance; however, levels of anti–MSP3c IgG3 an-
tibodies were twice as high in individuals who did not develop
malaria, compared with those who did. The association between
levels of IgG1 and protection against malaria attack was ob-
served to be significant for MSP3d ( ), and a similarPp .025
trend was observed for MSP3b ( ), but not for MSP3c.Pp .328
Neither IgG1 nor IgG3 responses to MSP3f were found to be
associated with protection. IgG2 and IgG4 antibody responses
against different regions of MSP3 were detected only at low
levels and were not found to be associated with protection.
In a further step, a multivariate stepwise regression anal-
ysis was performed to control for age, by use of dichotomous
variables of both antibody response (responders or nonre-
sponders) and occurrence of malaria attack (protected or non-
protected). A significant association of protection with IgG3
antipeptide responses was observed against 3 of 6 peptides—
MSP3b (Fp4.98, ), MSP3c ( , ), andPp .025 Fp 3.02 Pp .082
MSP3d ( , )—but not against the other 3.Fp 6.57 Pp .01
Inhibition of parasite growth by naturally occurring anti-
bodies against MSP3b, MSP3c, and MSP3d in functional in
vitro ADCI assays. To assess the function of naturally occur-
ring human antibodies to different regions of MSP3 in ADCI
assays, each affinity-purified antibody was adjusted to a concen-
tration that yielded the same reactivity to the native parasite
protein. Results (figure 4) showed that the level of parasite in-
hibition elicited by antibodies against the recombinant proteins
MSP3NT and MSP3CT were comparable to that observed for
the pool of African IgG (PIAG), which was used elsewhere for
a passive-transfer experiment in humans [6].
Anti–MSP3b, –MSP3c, and –MSP3d affinity-purified anti-
bodies were found to exert a strong monocytemediated antipara-
sitic activity in ADCI that was comparable to that of antibodies
against MSP3CT and PIAG, whereas anti–MSP3a and –MSP3f
antibodies were not found to have parasite inhibitory activity
(figure 4). Anti-MSP3e antibodies showed only marginal anti-
parasite activity that was slightly higher than the threshold level
of significance. Results were reproducible among 4 independent
ADCI assays. At the concentrations used, none of the above-
mentioned antibodies showed the direct inhibition of parasite
growth.
Strong reduction of P. falciparum parasitemia by anti–
MSP3b and anti–MSP3d antibodies in a humanized mouse
model. The observation from the in vitro ADCI assays that
anti–MSP3b, –MSP3c, and –MSP3d antibodies were strongly
effective at inhibiting parasite growth was further assessed in vi-
vo by use of the P. falciparum–HuRBC-BXN mouse model. The
value of this new mouse model for studying the in vivo effect
of human antibodies and antimalarial drugs on the blood-stage
growth of P. falciparum has been recently documented [16, 17].
We chose to study antibodies to MSP3d and MSP3f, which were
positive and negative in ADCI, respectively, compared with anti–
MSP3b antibodies, which we used as positive controls, whose
antiparasitic effect has already been demonstrated [16].
As seen in figure 5, the level of parasitemia increased and
reached a plateau over the next 3 weeks. The injection of an-
ti–MSP3f antibodies with human monocytes did not affect par-
asite growth, in agreement with the results of the in vitro ADCI
assays. In the other 2 mice, the injection of human monocytes
alone on day 22 did not affect parasite growth, in keeping with
earlier observations [16]. The injection of affinity-purified an-
ti–MSP3b or –MSP3d human antibodies on day 23 resulted in
a sharp decrease in parasitemia. The passive transfer of anti–
MSP3b antibodies resulted in the clearance of parasites. The
passive transfer of anti–MSP3d antibodies resulted in a de-
crease of parasitemia 195% (figure 5). Thus, results from the
in vivo passive transfer in this mouse model confirmed in vitro
results and further validated the functional antiparasite activ-
ity of naturally occurring antibodies against the 70-aa region
covered by peptides MSP3b and MSP3d.
T cell responses against MSP3 peptides in malaria-exposed
individuals. T lymphocyte responses could be studied against
only 3 (MSP3a, MSP3b, and MSP3c) of 6 C-terminal peptides
in inhabitants from Dielmo, Senegal, because of practical lim-
itations in field. The proliferative response, which was deter-
mined by use of peripheral blood lymphocytes from 61 indi-
viduals (age range, 1–84 years; mean age, 27.34 years) showed
that the prevalence of T helper cell responders was 16.4%
against MSP3a, 28% against MSP3b, and 21.3% against MSP3c,
respectively. IFN-g secretion, which was monitored in 31 of
these individuals, showed that the prevalence of IFN-g re-
sponders was 42% against MSP3a, 55% against MSP3b, and
61.3% against MSP3c. These results indicate that each of the
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Figure 4. Effect of affinity-purified human antibodies on parasite growth in antibody-dependent cellular inhibition assay. The histograms represent
mean values of the percentage of the specific growth inhibition index (SGI; as explained in the text) from 2 independent experiments SE; values
130% are significant. PIAG, positive control IgG from the pool of serum samples from adults from Ivory Coast used for passive-transfer experiments
in humans [6].
Figure 5. In vivo transfer of affinity-purified human anti–merozoite surface protein 3 (MSP3) antibodies, together with human peripheral blood monocytes
in P. falciparum–human red blood cell–Beige-Xid-Nude mice. The curves show the course of parasitemia as determined by microscopic examination of
thin blood smears from mice injected with anti–MSP3b antibodies (gray diamonds), anti–MSP3d antibodies (black circles), or control anti–MSP3f antibodies
that were ineffective in the antibody-dependent cellular inhibition assay (white circles). Arrows, days at which injections were made, first of human
monocytes (MNs) and then followed by monocytes together with anti–MSP3 antibodies (200 mL; immunofluorescence assay titer, 1:200).
3 MSP3 peptides tested defines at least 1 T cell epitope. In
addition, IFN-g secretion results suggested that at least some
of the responding cells belonged to the Th1-like type.
DISCUSSION
In the search for candidates for a malaria vaccine, we focused
our studies on antigens targeted by the most potent immu-
nity—that acquired over the years by individuals living in hy-
perendemic areas. We have described that this premunition is
mediated by IgG that is active through an indirect mechanism,
which implicates monocytes. We then used ADCI to identify
MSP3 as a target of protective IgG [12]. The present study was
aimed at characterizing antigens within the conserved C ter-
minus of MSP3 and evaluating the function and biological
effects of the corresponding antibodies.
Indeed, the C-terminal half of the molecule, starting from
the third heptad repeat, is highly conserved in the different
isolates tested so far [14, 15], whereas the N-terminal half of
MSP3 shows an overall dimorphism (3D7-like and K1-like)
[14, 15]. Therefore, we decided to focus on the C-terminal
region, because part of it (DG210; figure 1) was identified to
be a target of protective human antibodies in our initial study
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[12] and because antigen conservation is a critical criterion for
the successful development of a malaria vaccine.
Using 6 overlapping synthetic peptides covering the con-
served C-terminal half of MSP3, we have shown that antibody
patterns to each region differ markedly in terms of prevalence,
titer, isotype distribution, association with clinical protection,
and antiparasitic activity in vitro and in vivo. Antibody titers
against MSP3a and MSP3e were lower than those of the re-
maining 4 peptides. Responses to MSP3b, MSP3c, MSP3d, and
MSP3f were mostly of cytophilic IgG subclasses—predomi-
nantly of IgG1 isotype against MSP3f and IgG3 isotype against
the others. A similar difference in subclass response to distinct
regions of a single protein has been reported for MSP1 [26].
These observations suggest that IgG class switching involved
during the maturation of the antibody response toward dif-
ferent regions of the MSP3 C terminal is regulated indepen-
dently. The factors that regulate the maturation of antibodies
are not well understood but would be influenced by the nature
of the antigen in conjunction with contact-dependent signals
from T cells, particularly the cytokines they secrete [27]. Recent
observations, however, have suggested that the nature of the
malaria antigen might be the major factor that determines an-
tibody subclass [28], which seems to be the case in our study.
The availability of very detailed clinical information, which
is a major characteristic of the setup in the village of Dielmo,
Senegal, led us to address subclass patterns in relation to pro-
tection against the occurrence of malaria. Taking into account
the confounding effect of age, we observed that IgG3 responses
to MSP3b, MSP3c, and MSP3d were significantly associated
with protection. These results are in agreement with those of
independent studies that involved larger sample sizes [29] (C.
Oeuray, C.R., J.L. Pe´rignon C. Muller-Graf, A. Tall, C. Rogier,
J.F. Trape, and P.D., unpublished data), which have shown an
association between the IgG3 response against MSP3b and pro-
tection from malaria. For other merozoite surface vaccine can-
didates, a skewing toward the IgG3 antibody response has been
reported for MSP2 in various ethnic groups and under different
conditions of malaria transmission [30, 31]; this could be cor-
related with clinical immunity to malaria [32]. Similarly, the
antibody response to the polymorphic block 2 region of MSP1,
which has been identified as a target of immunity to clinical
malaria, is also skewed toward the IgG3 subclass [33]. However,
at least in the latter case, the mechanism of action of these
antibodies remains elusive, because it is generally assumed that
biologically active anti–MSP1 antibodies are directed to the C-
terminal part of the antigen [34].
In contrast, in the present study, the use of functional in
vitro ADCI assays provided information about the antiparasitic,
biological activity of antibodies toward various regions. Because
they were performed under conditions that allowed compari-
sons, they demonstrated critical differences in antibodies that
target different regions of MSP3. It is of interest that very dif-
ferent approaches led to similar conclusions—that is, the in vitro
ADCI assays pointed to the importance of exactly the same pep-
tides (MSP3b, MSP3c, and MSP3d) as those indicated by the
immunoepidemiological studies. The reasons for this lack of ef-
fect of antibodies to MSP3a and MSP3f remains to be investi-
gated. In the case of MSP3f, it is possible that antibodies might
not access this epitope on the merozoite surface, because the
leucine-zipper domain forms coiled-coil interactions with other
molecules [13, 14].
The reliability of in vitro findings could also be confirmed
under in vivo conditions [16]. On passive transfer in P. falci-
parum-infected mice grafted with human monocytes and with
long-lasting stable parasitemia, anti–MSP3b and –MSP3d an-
tibodies were found to be effective in reducing the P. falciparum
parasite load.
The vaccine potential of MSP3 was recently confirmed by the
protection elicited against P. falciparum challenge in Aotus nan-
cymai monkeys immunized with full-length MSP3 in Freund’s
adjuvant [35]. This observation is in agreement with our epi-
demiological and biological findings. However, the present study
has provided additional information derived from the analysis
of human immune responses for the design of future vaccine
constructs. Indeed, the N terminal of MSP3, although able to
induce antibody with functional activity in ADCI, is of debat-
able value, because of its polymorphism. Furthermore, its inclu-
sion could divert the immune response away from the important
conserved region. Within the C-terminal part, the region MSP3e–
f was also found to be less valuable, because of the low prevalence
and low levels of antibody response to MSP3e and anti–MSP3f
antibodies devoid of biological effect. Each of the 3 peptides
(MSP3a, MSP3b, and MSP3c) investigated proved to define a
non–cross-reactive T cell epitope for populations in endemic
areas. Recent vaccine trials performed using the construct defined
in the present study confirmed this finding and designated the
peptide MSP3d as an additional T cell–epitopic region (R. Au-
dran, M. Cachat, F. Lurati, S. Soe, O. Leroy, G.C., P.D., and F.
Spertini, unpublished data).
In summary, the results of immunoepidemiological studies
and functional assays led us to define a 70-aa region of the MSP3
molecule. We found that antibodies with antiparasitic effect de-
velop against this region, which covers MSP3b–MSP3d, in hu-
mans who have been naturally exposed to malaria. This infor-
mation is of practical value for future clinical trials for the rational
design of subunit vaccine constructs derived from MSP3.
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